Individuals tend to be more affected by vitiligo if it is visible on their face or hands, said David Rosmarin, MD, vice chair of research and education, Department of Dermatology, Tufts Medical Center.
David Rosmarin, MD, vice chair of research and education, Department of Dermatology, Tufts Medical Center, explains how vitiligo can impact a patient's quality of life, and why oral and topical treatment options are important.
Transcript
How does vitiligo affect a patient’s quality of life?
Vitiligo can be very impactful on patients' lives. We know from our research that oftentimes teenagers are very affected by their vitiligo. If patients have involvement of exposed areas such as the face or hands, they often are more affected by their disease. Additionally, if the disease is uncontrolled or progressive and somebody doesn't know when are they going to get another lesion, that also can really affect their quality of life. But every patient is different and some people are not as bothered, and we need to be able to accept everybody who has vitiligo and, for those who want to repigment, hopefully provide them that option.
Do you see a difference in adherence between topical and oral treatments?
It's important to have both an oral option to treat diseases as well as topicals. Orals can be particularly helpful for patients who have a large body surface area, or who find it inconvenient to use topicals, or maybe have progressive or unstable disease, whereas topical treatments are great because you avoid or minimize systemic exposure, and often are great for people who have more localized disease.
What's at Stake as Oral Arguments Are Presented in the Braidwood Case? Q&A With Richard Hughes IV
April 21st 2025Richard Hughes IV, JD, MPH, spoke about the upcoming oral arguments to be presented to the Supreme Court regarding the Braidwood case, which would determine how preventive services are guaranteed insurance coverage.
Read More
New Research Challenges Assumptions About Hospital-Physician Integration, Medicare Patient Mix
April 22nd 2025On this episode of Managed Care Cast, Brady Post, PhD, lead author of a study published in the April 2025 issue of The American Journal of Managed Care®, challenges the claim that hospital-employed physicians serve a more complex patient mix.
Listen
Orca-T showed lower rates of graft-vs-host disease or infection compared with allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome (MDS) or acute leukemias in the Precision-T trial, Caspian Oliai, MD, MS, UCLA Bone Marrow Transplantation Stem Cell Processing Center, said.
Read More
Personalized Care Key as Tirzepatide Use Expands Rapidly
April 15th 2025Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Listen
Managing Skin Conditions: Highlighting Ruxolitinib Cream, Phototherapy Efficacy and Cost
April 8th 2025Research presented at the 2025 Academy of Managed Care Pharmacy annual meeting analyzed real-world treatment outcomes for dermatologic conditions, specifically highlighting the efficacy of ruxolitinib cream for atopic dermatitis and the potential for phototherapy to delay costly biologic initiation.
Read More